American Society of Hirudotherapy

Clinical Analysis of Heparin-Induced Thrombocytopenia due to Therapeutic Plasmapheresis With Heparin Anticoagulation

Research article published in Seminars in dialysis (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureLv C et al. · Seminars in dialysis, 2025

Abstract

OBJECTIVE: We investigated the clinical characteristics and treatment outcomes of heparin-induced thrombocytopenia (HIT) following therapeutic plasma exchange (TPE) with heparin anticoagulation in patients with neurological autoimmune diseases. METHODS: Clinical data were prospectively collected from 158 patients (79 males, 79 females; mean age 37.49 ± 16.95 years) with neurological autoimmune diseases who underwent TPE in the neuro-intensive care unit between January 2016 and June 2024. For patients with continuous platelet decline after TPE, the 4Ts score was determined, and platelet factor 4 (PF4) antibody tests were performed. Their platelet counts, clinical complications (thrombosis and bleeding), treatment plans, outcomes, and prognoses before and after TPE were analyzed. RESULTS: One hundred thirty-nine patients experienced at least one significant decrease in platelet count during TPE (average decrease 36.75 ± 19.63%), and the average 4Ts score was 3.55 ± 1.87 points. PF4 antibody testing was conducted on 23 patients with continuous platelet decline and 4Ts scores ≥ 4. Four PF4-positive patients were diagnosed with type II HIT and developed deep vein thrombosis. After heparin withdrawal, the platelet count gradually normalized after intravenous immunoglobulin (IVIG), nonheparin TPE, or argatroban/fondaparinux anticoagulant therapy (mean recovery time 8.17 ± 3.54 days). The platelet counts spontaneously recovered for the remaining 116 patients (mean recovery time 3.88 ± 2.66 days). CONCLUSION: Platelet counts should be dynamically monitored throughout TPE with heparin anticoagulation. Patients with continually decreasing platelet counts and an intermediate to high 4Ts score should be monitored for HIT. Heparin should be discontinued immediately for patients with type II HIT, and nonheparin anticoagulants, IVIG, or nonheparin TPE may be administered.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansMaleFemaleHeparinThrombocytopeniaAnticoagulantsPlasmapheresisMiddle AgedAdultProspective StudiesPlatelet CountAgedPlasma ExchangeAutoimmune Diseases

Summary

Among 158 neurological autoimmune-disease patients undergoing heparin-anticoagulated therapeutic plasma exchange, four developed type II HIT with deep vein thrombosis; platelet counts recovered after heparin withdrawal plus IVIG, nonheparin plasma exchange, or argatroban/fondaparinux (mean 8.17 days).

Why This Matters for Hirudotherapy

This study prospectively collected clinical data from 158 patients with neurological autoimmune diseases who underwent therapeutic plasma exchange (TPE) with heparin anticoagulation in a neuro-intensive care unit, identifying four patients diagnosed with type II heparin-induced thrombocytopenia (HIT) who developed deep vein thrombosis. The findings highlight the ongoing clinical challenge of HIT and the critical need for effective non-heparin anticoagulant alternatives—a therapeutic area where direct thrombin inhibitors derived from or modeled on medicinal-leech hirudin, including lepirudin, desirudin, and bivalirudin, have historically contributed. The study documents HIT occurrence during heparin-anticoagulated TPE and clinical management with non-heparin agents, providing context relevant to understanding when hirudin-based anticoagulants may be clinically indicated. However, this study used argatroban or fondaparinux as alternative anticoagulants and did not specifically investigate hirudin-derived agents, so it provides no direct evidence of their efficacy in this setting.

Citation

Reference (Vancouver style)

Lv C, Liang H, Tian F, Liu G, Chen W, Zhang Y. Clinical Analysis of Heparin-Induced Thrombocytopenia due to Therapeutic Plasmapheresis With Heparin Anticoagulation. Semin Dial. 2025;38(4):267-275. doi:10.1111/sdi.13259. PMID: 40420535

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.